Epidermal growth factor receptor (EGFR)-sensitizing mutation, exon 19 deletion consists of several molecular variants. Influences of these variants on clinical response to EGFR tyrosine kinase inhibitors remain elusive. | Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy